李广欣;张钰;黎功;

• 1:北京清华长庚医院放疗科

摘要(Abstract)：

2018年欧洲临床肿瘤协会(European Society for Medical Oncology, ESMO)发布了最新版肝细胞癌治疗指南,就肝细胞癌流行病学特征、发病前的监测、诊断、分期、治疗、疗效评估等内容进行了详细阐述,其中不乏内容的更新和补充。本文就2018版ESMO肝细胞癌指南进行解读。

关键词(KeyWords)： 肝细胞癌;指南;欧洲临床肿瘤协会;解读

Abstract:

Keywords:

基金项目(Foundation): 国家科技重大专项(2017YFC0112100);; “十三五”国家科技重大专项——新药创制专项(2017ZX09309023)

作者(Authors): 李广欣;张钰;黎功;

参考文献(References)：

• [1]Petrick JL,Kelly SP,Altekruse SF,et al.Future of hepatocellular carcinoma incidence in the United States forecast through2030[J].J Clin Oncol,2016,34(15):1787-1794.
• [2]White DL,Thrift AP,Kanwal F,et al.Incidence of hepatocellular carcinoma in all 50 United States,from 2000 through2012[J].Gastroenterology,2017,152(4):812-820,e5.
• [3]郑侠,陈晓锋.肝细胞癌系统治疗研究进展[J].肿瘤综合治疗电子杂志,2018,4(3):37-43.
• [4]Paradis V,Zalinski S,Chelbi E,et al.Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis:a pathological analysis[J].Hepat ology,2009,49(3):851-859.
• [5]International Consensus Group for Hepatocellular Neoplasia The International Consensus Group for Hepatocellular Neoplasia.Pathologic diagnosis of early hepatocellular carcin oma:a report of the international consensus group for hepato cellular neoplasia[J].Hepatology,2009,49(2):658-664.
• [6]Sciarra A,Di Tommaso L,Nakano M,et al.Morphophenotypic changes in human multistep hepatocarcinogenesis with translational implications[J].J Hepatol,2016,64(1):87-93.
• [7]Calderaro J,Couchy G,Imbeaud S,et al.Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification[J].J Hepatol,2017,67(4):727-738.
• [8]Yeh MM,Liu Y,Torbenson M.Steatohepatitic variant of hepatocellular carcinoma in the absence of metabolic syndrome or background steatosis:a clinical,pathological,and genetic study[J].Hum Pathol,2015,46(11):1769-1775.
• [9]Silva MA,Hegab B,Hyde C,et al.Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer:a systematic review and meta-analysis[J].Gut2008,57(11):1592-1596.
• [10]Boussouar S,Itti E,Lin SJ,et al.Functional imaging of hepatocellular carcinoma using diffusion-weighted MRI and(18)F-FDGPET/CT in patients on waiting-list for liver trans plantation[J].Cancer Imaging,2016,16:4.
• [11]Hyun SH,Eo JS,Song BI,et al.Preoperative prediction of microvascular invasion of hepatocellular carcinoma using18F-FDG PET/CT:a multi-center retrospective cohort study[J].Eur J Nucl Med Mol Imaging,2018,45(5):720-726.
• [12]Mazzaferro V,Llovet JM,Miceli R,et al.Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria:a retrospective,exploratory analysis[J].Lancet Oncol,2009,10(1):35-43.
• [13]Yao FY.Liver transplantation for hepatocellular carcinoma:beyond the Milan criteria[J].Am J Transplant,2008,8(10):1982-1989.
• [14]Cucchetti A,Piscaglia F,Cescon M,et al.Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma[J].J Hepatol,2013,59(2):300-307.
• [15]Geissler EK,Schnitzbauer AA,Zulke C,et al.Sirolimus use in liver transplant recipients with hepatocellular carcinoma:a randomized,multicenter,open-label phase 3 trial[J].Transplantation,2016,100(1):116-125.
• [16]Bruix J,Takayama T,Mazzaferro V,et al.Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation(STORM):a phase 3,randomised,double-blind,placebo-contr olled trial[J].Lancet Oncol,2015,16(13):1344-1354.
• [17]Zeng ZC,Seong J,Yoon SM,et al.Consensus on stereotactic body radiation therapy for small-sized hepatocellular carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting[J].Liver Cancer,2017,6(4):264-274.
• [18]Denecke T,Stelter L,Schnapauff D,et al.CT-guided Interstitial Brachytherapy of Hepatocellular Carcinoma before Liver Transplantation:an Equivalent Alternative to Transarterial Chemoembolization?[J].Eur Radiol,2015,25(9):2608-2616.
• [19]Mohnike K,Wieners G,Schwartz F,et al.Computed tomography-guided high-dose-rate brachytherapy in hepatoce llular carcinoma:safety,efficacy,and effect on survival[J].Int JRadiat Oncol Biol Phys,2010,78(1):172-179.
• [20]Collettini F,Schreiber N,Schnapauff D,et al.CT-guided high-dose-rate brachytherapy of unresectable hepatocellular carcinoma[J].Strahlenther Onkol,2015,191(5):405-412.
• [21]Cucchetti A,Piscaglia F,Cescon M,et al.Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma[J].J Hepatol,2013,59(2):300-307.
• [22]Chow PKH,Gandhi M,Tan SB,et al.SIRve NIB:selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma[J].J Clin Oncol,2018,36(9):1913-1921.
• [23]Vilgrain V,Pereira H,Assenat E,et al.Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma(SARAH):an open-label randomised controlled phase 3 trial[J].Lancet Oncol,2017,18(7):1624-1636.
• [24]Yeo W,Mok TS,Zee B,et al.A randomized phaseⅢstudy of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil(PIAF)combination chemotherapy for unresectable hepatocellular carcinoma[J].J Natl Cancer Inst,2005,97(20):1532-1538.
• [25]Gish RG,Porta C,Lazar L,et al.PhaseⅢrandomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin[J].J Clin Oncol,2007,25(21):3069-3075.
• [26]Qin S,Bai Y,Lim HY,et al.Randomized,multicenter,openlabel study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J].J Clin Oncol,2013,31(28):3501-3508.
• [27]El-Khoueiry AB,Sangro B,Yau T,et al.Nivolumab in patients with advanced hepatocellular carcinoma(Check Mate 040):an open-label,non-comparative,phase 1/2 dose escalation and expansion trial[J].Lancet,2017,389(10088):2492-2502.
• [28]Zhu AX,Finn RS,Edeline J,et al.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib(KEYNOTE-224):a non-randomised,openlabel phase 2 trial[J].Lancet Oncol,2018,19(7):940-952.